ABSTRACT
Objective To investigate the effect of atorvastain on plasma levels of nitric oxide(NO) and alpha-granule membrance protein-140(GMP-140) in patients with acute cerebral infarction.Methods 94 cases with acute cerebral infarction were randomly divided into the atorvastain group(48 cases) and the control group(46 cases).Plasma NO and GMP-140 were determined by the method of nitrate reductase and enzyme-linked immunosorbent assay in atorvastain group and control group at moment of hospitalization and after four weeks.Results Plasma NO and GMP-140 of atorvastain group after treatment were statistically lower than that of controls(P0.05).Conclusion Atorvastain can reduce plasma levels of NO and GMP-140 in patients with acute cerebral infarction.It can ameliorate brain injury after ischemia and has protective effect on the ischemia cerebral tissue.
ABSTRACT
Objective To observe the effects of recombinant staphylokinase (r-SAK) on platelet activation parameters in patients with acute myocardial infarction(AMI) by intravenous thrombolysis in order to investigate the clinical thrombolytic efficacy of r-SAK therapy in AMI comparing with recombinant tissue-type plasminogen activator(rt-PA) therapy.Methods Thirty-three patients with AMI within 12 h after the onset were selected and divided randomly into the r-SAK therapy group(n=17) and rt-PA therapy group(n=16).Coronary artery angiography(CAG) was performed 90 min after thrombolytic therapy in patients.Thrombin-antithrombin complex(TAT) and alpha granule membrane protein(GMP-140) were measured by similar commercial enzyme-linked immunosorbent assay(ELISA).Results In r-SAK group and rt-PA group,the plasma contents of GMP-140 2 h after thrombolytic therapy were significantly higher than before therapy(P0.05).In rt-PA group,the plasma content of TAT 2 h after thrombolytic therapy increased significantly(P0.05).) Conclusion r-SAK has similar effect with rt-PA and it will become available for highly fibrin-selective thrombolytic therapy of AMI.Thrombolytic treatment with r-SAK can improve the injury of myocardial microperfusion.